Do analysts prefer SLXN or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SLXN or PPCB?

Propanc Biopharma is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is SLXN or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Propanc Biopharma N/A -151.28% -109.53%

Does the media prefer SLXN or PPCB?

In the previous week, Silexion Therapeutics had 5 more articles in the media than Propanc Biopharma. MarketBeat recorded 9 mentions for Silexion Therapeutics and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.72 beat Silexion Therapeutics' score of 0.45 indicating that Propanc Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLXN or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 21,359.23%. Given GeoVax Labs' higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SLXN or GOVX more profitable?

Silexion Therapeutics' return on equity of -516.86% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% GeoVax Labs N/A -743.64% -394.74%

Does the media favor SLXN or GOVX?

In the previous week, Silexion Therapeutics had 4 more articles in the media than GeoVax Labs. MarketBeat recorded 9 mentions for Silexion Therapeutics and 5 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.57 beat Silexion Therapeutics' score of 0.45 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SLXN or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 719.45%. Given Decoy Therapeutics' higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, SLXN or DCOY?

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is SLXN or DCOY more profitable?

Decoy Therapeutics' return on equity of -309.31% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Decoy Therapeutics N/A -309.31% -169.48%

Do analysts rate SLXN or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SLXN or BIAF?

In the previous week, Silexion Therapeutics had 4 more articles in the media than bioAffinity Technologies. MarketBeat recorded 9 mentions for Silexion Therapeutics and 5 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.98 beat Silexion Therapeutics' score of 0.45 indicating that bioAffinity Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GNPX or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, GNPX or SLXN?

Genprex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$310.77 N/A Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A

Is GNPX or SLXN more profitable?

Genprex's return on equity of -247.32% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Silexion Therapeutics N/A -516.86% -176.68%

Silexion Therapeutics (SLXN) Competitors

$0.39 -0.07 (-15.00%)

As of 11:16 AM Eastern

Compare

SLXN vs. PPCB, GOVX, DCOY, BIAF, and GNPX

Should you buy Silexion Therapeutics stock or one of its competitors? Silexion Therapeutics's main competitors and comparable companies include Propanc Biopharma (PPCB), GeoVax Labs (GOVX), Decoy Therapeutics (DCOY), bioAffinity Technologies (BIAF), and Genprex (GNPX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silexion Therapeutics compare to Propanc Biopharma?

Silexion Therapeutics (NASDAQ:SLXN) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Propanc Biopharma's return on equity of -151.28% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Propanc Biopharma	N/A	-151.28%	-109.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

11.0% of Silexion Therapeutics shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Silexion Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market.

In the previous week, Silexion Therapeutics had 5 more articles in the media than Propanc Biopharma. MarketBeat recorded 9 mentions for Silexion Therapeutics and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.72 beat Silexion Therapeutics' score of 0.45 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Silexion Therapeutics and Propanc Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Silexion Therapeutics compare to GeoVax Labs?

Silexion Therapeutics (NASDAQ:SLXN) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 21,359.23%. Given GeoVax Labs' higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Silexion Therapeutics has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
GeoVax Labs	$2.49M	0.97	-$21.47M	-$11.34	N/A

In the previous week, Silexion Therapeutics had 4 more articles in the media than GeoVax Labs. MarketBeat recorded 9 mentions for Silexion Therapeutics and 5 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.57 beat Silexion Therapeutics' score of 0.45 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by insiders. Comparatively, 0.7% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Silexion Therapeutics' return on equity of -516.86% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
GeoVax Labs	N/A	-743.64%	-394.74%

Silexion Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, meaning that its share price is 273% more volatile than the broader market.

Summary

Silexion Therapeutics beats GeoVax Labs on 9 of the 14 factors compared between the two stocks.

How does Silexion Therapeutics compare to Decoy Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Decoy Therapeutics' return on equity of -309.31% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Decoy Therapeutics	N/A	-309.31%	-169.48%

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 719.45%. Given Decoy Therapeutics' higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Silexion Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 7 more articles in the media than Decoy Therapeutics. MarketBeat recorded 9 mentions for Silexion Therapeutics and 2 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.47 beat Silexion Therapeutics' score of 0.45 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Silexion Therapeutics	Neutral
Decoy Therapeutics	Positive

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by insiders. Comparatively, 1.5% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Decoy Therapeutics beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to bioAffinity Technologies?

Silexion Therapeutics (NASDAQ:SLXN) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Silexion Therapeutics had 4 more articles in the media than bioAffinity Technologies. MarketBeat recorded 9 mentions for Silexion Therapeutics and 5 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.98 beat Silexion Therapeutics' score of 0.45 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Silexion Therapeutics has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$7.30	N/A

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 4.1% of Silexion Therapeutics shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silexion Therapeutics has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. bioAffinity Technologies' return on equity of -196.80% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
bioAffinity Technologies	-257.30%	-196.80%	-128.23%

Silexion Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.05, indicating that its stock price is 205% less volatile than the broader market.

Summary

Silexion Therapeutics beats bioAffinity Technologies on 9 of the 14 factors compared between the two stocks.

How does Silexion Therapeutics compare to Genprex?

Genprex (NASDAQ:GNPX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Silexion Therapeutics had 6 more articles in the media than Genprex. MarketBeat recorded 9 mentions for Silexion Therapeutics and 3 mentions for Genprex. Genprex's average media sentiment score of 1.44 beat Silexion Therapeutics' score of 0.45 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Positive
Silexion Therapeutics	Neutral

14.1% of Genprex shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 0.3% of Genprex shares are held by insiders. Comparatively, 4.1% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genprex has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Genprex's return on equity of -247.32% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Silexion Therapeutics	N/A	-516.86%	-176.68%

Genprex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

Summary

Silexion Therapeutics beats Genprex on 9 of the 12 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163K	$3.69B	$6.96B	$13.10B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	0.00	10.23	269.57	25.32
Price / Sales	N/A	1,285.96	595.01	100.00
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.05	17.54	13.06	6.29
Net Income	-$11.91M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-79.25%	0.19%	0.47%	0.89%
1 Month Performance	-84.48%	-0.03%	1.11%	0.85%
1 Year Performance	-99.47%	53.11%	66.38%	20.25%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	0.6745 of 5 stars	$0.39 -15.7%	N/A	-99.4%	$163K	N/A	N/A	N/A	Earnings Report Short Interest Increase Gap Down
PPCB Propanc Biopharma	1.1383 of 5 stars	$1.28 +25.5%	N/A	-99.4%	$2.92M	N/A	N/A	1	Analyst Upgrade Short Interest Decrease Gap Up
GOVX GeoVax Labs	2.7863 of 5 stars	$0.76 flat	$150.00 +19,585.0%	-96.1%	$2.64M	$2.49M	N/A	10	News Coverage Short Interest Decrease
DCOY Decoy Therapeutics	2.2073 of 5 stars	$4.26 -2.6%	$30.00 +604.9%	N/A	$2.53M	N/A	N/A	20	Earnings Report Gap Down
BIAF bioAffinity Technologies	0.8107 of 5 stars	$0.53 -3.5%	N/A	-95.4%	$2.51M	$6.16M	N/A	10	News Coverage Earnings Report Upcoming Earnings Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. PPCB, GOVX, DCOY, BIAF, and GNPX

How does Silexion Therapeutics compare to Propanc Biopharma?

Summary

How does Silexion Therapeutics compare to GeoVax Labs?

Summary

How does Silexion Therapeutics compare to Decoy Therapeutics?

Summary

How does Silexion Therapeutics compare to bioAffinity Technologies?

Summary

How does Silexion Therapeutics compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. PPCB, GOVX, DCOY, BIAF, and GNPX

How does Silexion Therapeutics compare to Propanc Biopharma?

Is SLXN or PPCB more profitable?

Do analysts prefer SLXN or PPCB?

Which has higher valuation & earnings, SLXN or PPCB?

Do institutionals and insiders hold more shares of SLXN or PPCB?

Which has more risk and volatility, SLXN or PPCB?

Does the media prefer SLXN or PPCB?

Summary

How does Silexion Therapeutics compare to GeoVax Labs?

Do analysts recommend SLXN or GOVX?

Which has stronger valuation and earnings, SLXN or GOVX?

Does the media favor SLXN or GOVX?

Do institutionals & insiders have more ownership in SLXN or GOVX?

Is SLXN or GOVX more profitable?

Which has more risk and volatility, SLXN or GOVX?

Summary

How does Silexion Therapeutics compare to Decoy Therapeutics?

Is SLXN or DCOY more profitable?

Do analysts rate SLXN or DCOY?

Which has more volatility & risk, SLXN or DCOY?

Does the media refer more to SLXN or DCOY?

Which has preferable valuation & earnings, SLXN or DCOY?

Do insiders and institutionals believe in SLXN or DCOY?

Summary

How does Silexion Therapeutics compare to bioAffinity Technologies?

Does the media favor SLXN or BIAF?

Do analysts rate SLXN or BIAF?

Which has preferable earnings and valuation, SLXN or BIAF?

Do institutionals and insiders hold more shares of SLXN or BIAF?

Is SLXN or BIAF more profitable?

Which has more volatility & risk, SLXN or BIAF?

Summary

How does Silexion Therapeutics compare to Genprex?

Do analysts rate GNPX or SLXN?

Does the media prefer GNPX or SLXN?

Do institutionals & insiders have more ownership in GNPX or SLXN?

Which has more risk and volatility, GNPX or SLXN?

Is GNPX or SLXN more profitable?

Which has higher valuation and earnings, GNPX or SLXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools